Results 11 to 20 of about 395,984 (223)
Delayed Onset Malignant Hyperthermia after Sevoflurane
Case Reports in Anesthesiology, 2013 Malignant hyperthermia is a hypermetabolic response to inhalation agents (such as halothane, sevoflurane, and desflurane), succinylcholine, vigorous exercise, and heat. Reactions develop more frequently in males than females (2 : 1).
K. Sanem Cakar Turhan +3 more
doaj +2 more sources
Successful management of malignant hyperthermia without dantrolene: A case report [PDF]
Journal of International Medical ResearchMalignant hyperthermia during surgery represents a significant challenge for anesthesiologists due to its high mortality rate and the risk of long-term physiological damage.
Cailing Zhang +3 more
doaj +2 more sources
Genetics of Malignant Hyperthermia
Scientific World Journal, The, 2006 Study of the genetics of the malignant hyperthermia syndrome began in families in which both malignant hyperthermia (MH) episodes had been experienced and individuals had strongly positive contracture tests diagnostic of susceptibility to MH.
Barbara W. Brandom
exaly +2 more sources
Keeping it in the family: malignant hyperthermia - how we predict, recognise and treat it [PDF]
Brazilian Journal of AnesthesiologyJonathan G. Bilmen, Pawan K. Gupta
doaj +2 more sources
Acute postoperative sepsis mimicking symptomology suspicious for malignant hyperthermia: case report [PDF]
Revista Brasileira de Anestesiologia, 2020 Background: Sepsis is a life-threatening organ dysfunction with non-specific clinical features that can mimic other clinical conditions with hyper metabolic state such as malignant hyperthermia.
Vendhan Ramanujam +3 more
doaj +5 more sources
Medical Journal of Dr. D.Y. Patil University, 2014 Although very rare, occurring one out of every 100,000 anesthesia cases, malignant hyperthermia is a hypermetabolic disorder that anesthesia providers screen and interrogate patients prior to every case they are administering anesthesia.
Kirti N Saxena
doaj +5 more sources
Malignant Hyperthermia in PICU—From Diagnosis to Treatment in the Light of Up-to-Date Knowledge
Children, 2022 Malignant Hyperthermia (MH) is a rare, hereditary, life-threatening disease triggered by volatile anesthetics and succinylcholine. Rarely, MH can occur after non-pharmacological triggers too. MH was detected more often in children and young adults, which
Martina Klincová +4 more
doaj +1 more source
Profile of malignant hyperthermia susceptibility reports confirmed with muscular contracture test in Brazil [PDF]
Revista Brasileira de Anestesiologia, 2019 Background and objectives: Malignant hyperthermia is an autosomal dominant hypermetabolic pharmacogenetic syndrome, with a mortality rate of 10%–20%, which is triggered by the use of halogenated inhaled anesthetics or muscle relaxant succinylcholine. The
Helga Cristina Almeida da Silva +7 more
doaj +5 more sources
Impact of a digital manual for guidance on malignant hyperthermia: patient education
Orphanet Journal of Rare Diseases, 2022 Background Malignant hyperthermia (MH) is a rare, hereditary disease with a hypermetabolic response to volatile anesthetics/succinylcholine. Susceptible patients face difficulties due to a lack of knowledge about MH.
Gislene Rodrigues +4 more
doaj +1 more source
Malignant hyperthermia: a case report with a literature review [PDF]
Archives of Aesthetic Plastic Surgery, 2022 Malignant hyperthermia is an extremely rare, potentially lethal disorder that occurs in susceptible patients who are exposed to triggering agents such as volatile anesthetic gases or depolarizing muscle relaxants. The clinical manifestations of malignant
Ji Hoon Kim +4 more
doaj +1 more source